Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice

Journal of Clinical Investigation

Volumn 108, Issue 2, 2001, Pages 261-268

  Yamamoto, Yasuhiko ^a,b   Kato, Ichiro ^b   Doi, Toshio ^c   Yonekura, Hideto ^a   Ohashi, Seiji ^c   Takeuchi, Masayoshi ^d   Watanabe, Takuo ^a   Yamagishi, Sho Ichi ^a   Sakurai, Shigeru ^a   Takasawa, Shin ^b   Okamoto, Hiroshi ^b   Yamamoto, Hiroshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

^d HOKURIKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; ACETANILIDE DERIVATIVE; CREATININE; GENE PRODUCT; HEMOGLOBIN A1C; PROTEIN RAGE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES CONTROL; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG TARGETING; GENE OVEREXPRESSION; GLOMERULOSCLEROSIS; GLOMERULUS; HEMOGLOBIN DETERMINATION; HEREDITY; HYPERTROPHY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY SIZE; LIFE EXPECTANCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TRANSGENIC MOUSE;

EID: 0034947508     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI11771     Document Type: Article

References (53)

1. Declining incidence of nephropathy in insulin-dependent diabetes mellitus
2. Magnitude of end-stage renal disease in IDDM: A 35 year follow-up study
3. Animal models of spontaneous diabetic kidney disease
4. Glomerular lesions in nonobese diabetic mouse: Before and after the onset of hyperglycemia
5. Increased vascular permeability in spontaneously diabetic BB/W rats and in rats with mild versus severe streptozotocin-induced diabetes. Prevention by aldose reductase inhibitors and castration
6. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
7. Advanced glycosylation end products induce glomerular sclerosis and albuminuria in normal rats
8. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease
9. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats
10. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface
11. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins
12. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor
13. Advanced glycation end products inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells
14. Receptor-mediated toxicity to pericytes of advanced glycosylation end products: A possible mechanism of pericyte loss in diabetic microangiopathy
15. Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells
16. Transgenic mice overexpressing type 2 nitric-oxide synthase in pancreatic β cells develop insulin-dependent diabetes without insulitis
17. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation
18. Characterization of the endothelium-specific murine growth factor receptor-2 (Flk-1) promoter
19. Recombination and amplification of multiple portions of genomic DNA by a modified polymerase chain reaction
20. Three genes in the human MHC class III region near the junction with the class II: Gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and Notch homolog, human counterpart of mouse mammary tumor gene int-3
21. Rapid determination of haemoglobin A1c and glucose in mice: Strain differences, glucose tolerance tests and neonatal streptozotocin-induced diabetic model
22. Advanced glycation end products-receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factor-B
23. Improved method for the isolation of mouse glomeruli
24. 2+ mobilization in normal and diabetic β-cells
25. A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants
26. Effects of granulocyte-macrophage colony-stimulating factor on eicosanoid production by mononuclear phagocytes
27. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
28. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients
29. On the colorimetric determination of creatinine by the Jaffe reaction
30. Glomerular lesions in mice transgenic for growth hormone and insulinlike growth factor-1. Relationship between increased glomerular size and mesangial sclerosis
31. Role of growth hormone in the development of experimental renal scarring
32. Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulin like growth factor-1
33. Angiotensin II type 1 receptor blockade inhibits the expression of immediate-early genes and fibronectin in rat injured artery
34. Glomerulosclerosis in mice transgenic for growth hormone. Increased mesangial extracellular matrix is correlated with kidney mRNA levels
35. Streptozotocin and alloxan induce DNA strand breaks and poly(ADP-ribose) synthetase in pancreatic islets
36. The molecular basis of experimental diabetes
37. Microalbuminuria, blood pressure and diabetic renal disease: Origin and development of ideas
38. The receptor for advanced glycation end products is induced by the glycation products themselves and TNF-α through NF-κB, and by 17β-estradiol through Sp-1 in human vascular endothelial cells
39. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues
40. Expression of receptors for advanced glycosylated end-products in renal disease
41. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease
42. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2 microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis
43. Vascular permeability, factor: A unique regulator of blood vessel function
44. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins
45. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy
46. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor
47. Advanced glycation end products modulate transcriptional regulation in mesangial cells
48. The endothelial cell binding site for advanced glycation end products consists of a complex: An integral membrane protein and a lactoferrin-like polypeptide
49. Conditional requirement for the Flk-1 receptor in the in vitro generation of early hematopoietic cells
50. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system
51. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeprides
52. The S100 family of EF-hand calcium-binding proteins: Functions and pathology
53. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products